Search for content, post, videos

Dilafor signs agreement with Opocrin

Swedish Dilafor AB and Italian Opocrin S.p.A. have entered into a commercial supply and partnership agreement.

In the agreement, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for Dilafor’s candidate drug tafoxiparin for the European, US, CIS and Japanese markets. Opocrin will also supply manufacturing services during clinical development of tafoxiparin and the companies will jointly develop the commercial manufacturing of tafoxiparin.

The partnership will initially focus on the clinical supply of tafoxiparin in support of the Phase II and Phase III clinical trial program in obstetrical indications. Opocrin will support the company with services and manufacturing needed to take tafoxiparin through those clinical studies and by preparing for the commercial supply of tafoxiparin for major markets such as US, EU, Japan and CIS.

“We are looking forward working together with Opocrin in this exciting and important phase in the development of tafoxiparin. Opocrin has extensive experience in the manufacturing of polysaccharide derivatives such as tafoxiparin making them an excellent commercial partner for Dilafor,” says Lena Degling Wikingsson, CEO at Dilafor AB.